预印本 / 版本 1

Alternative tandem transcription initiation links noncoding variants to human disease through translational control

本文是预印本,尚未经过同行评审认证。

作者

    Xudong Zou,  Wei Wang,  Xing Li,  Yinuo Wang,  Hui Chen,  Shuxin Chen,  Feihong Weng,  Qin Li,  Chen Yu,  Lei Li
    Lei Li
分类
关键词
Alternative transcription initiation; translational regulation; cancer risk

摘要

Alternative tandem transcription initiation (ATI) is a pervasive mechanism of gene regulation, yet its genetic impact on human disease remains largely unknown. Here, we systematically quantified genetic regulation of ATI across 25,859 samples from 49 human normal tissues and 33 tumor tissues. We identified ~0.4 million 5′ UTR ATI quantitative trait loci (5′aQTLs) in 5,295 genes, with 32% operating independently of gene expression. Moreover, we discovered 2,238 multi-tissue ATI outliers enriched for rare deleterious promoter and 5′ UTR variants, demonstrating that both common and rare variants modulate transcription initiation. Strikingly, 74% of disease variants that colocalize with 5′aQTLs cannot be identified by eQTLs. Transcriptome-wide association studies identified 614 ATI-mediated disease susceptibility genes, including known cancer drivers such as MAFF and MLLT10. Functional validation uncovered OSGEP as a novel breast cancer risk gene, where the alternative allele lengthens the 5′ UTR and reduces protein abundance through upstream open reading frame (uORF)-mediated translation repression, and suppresses breast cancer cell proliferation. Our findings establish ATI as a major, underappreciated mechanism linking noncoding variation to disease, providing a critical resource for interpreting disease risk loci.

指标

收藏: 2
查看次数: 651
下载次数: 184

DOI:

Submission ID:

14

下载次数

已发布

2025-11-19

如何引用

Zou, X., Wang, W., Li, X., Wang, Y., Chen, H., Chen, S., Weng, F., Li, Q., Yu, C., & Li, L. (2025). Alternative tandem transcription initiation links noncoding variants to human disease through translational control. 浪淘沙预印本平台. https://doi.org/10.65215/8cvbsy26

利益冲突声明

作者声明无任何需要披露的利益冲突。